Riskpilot← Back to searchSign inGet full accessGlycorex Transplantation AB (publ)
ABActiveOrg 5565197372Scheelevägen 27Research and experimental development on natural sciences and engineering · NACE 7210Est. 199514 employees
Revenue 2024
SEK 35,2M
+17% vs 2023
EBITDA margin
-23.0%
+48% vs 2023
Equity ratio
80.0%
Financial strength
Net profit 2024
SEK -10,9M
+64% vs 2023
| Revenue | SEK 35,2M | +17% |
| EBITDA | SEK -8,1M | +48% |
| Net profit | SEK -10,9M | +64% |
| Total assets | SEK 40,8M | -21% |
| Equity | SEK 32,6M | -25% |
| Employees | 14 | — |
Legal name
Glycorex Transplantation AB (publ)
Org number
5565197372
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
13 juli 1995
Share capital
SEK 3 692 000
Employees
14 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas av Nilsson, Johan Martin Ingemar i förening med en av ledamöterna Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall, utveckla, tillverka och marknadsföra biotekniska produkter inom området för (1) transplantioner och (2) blod- behandlingar och därmed relaterade produkter, samt idka därmed förenlig verksamhet.
Address
Scheelevägen 27
Email
adm@glycorex.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 27 000 | 28 202 | 36 116 | 29 962 | 35 159 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −5 304 | −8 102 | −6 175 | −15 581 | −8 092 |
| Depreciation & amort. | −2 229 | −2 351 | −2 705 | −8 183 | −2 785 |
| EBIT | −7 533 | −10 453 | −8 880 | −23 764 | −10 877 |
| Net financials | 14 | −279 | −3 207 | −6 719 | −112 |
| Profit before tax | −7 518 | −12 274 | −12 063 | −30 386 | −10 853 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −7 518 | −12 274 | −12 063 | −30 386 | −10 853 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 104 787 | 94 422 | 83 182 | 51 784 | 40 799 |
| Equity | 98 196 | 85 922 | 73 859 | 43 472 | 32 620 |
| Long-term debt | 0 | 232 | 132 | 33 | 0 |
| Short-term debt | 6 591 | 8 268 | 9 191 | 8 279 | 8 179 |
| Total debt | 6 591 | 8 500 | 9 323 | 8 312 | 8 179 |
EBITDA margin
-23.0%
This company
15.8%
Market median
-246% vs market
20202024
Equity ratio
80.0%
This company
38.2%
Market median
+109% vs market
20202024
Return on equity
-33.3%
This company
18.4%
Market median
-281% vs market
20202024
Net profit margin
-30.9%
This company
8.1%
Market median
-481% vs market
20202024
Asset turnover
0.86×
This company
1.12×
Market median
+23% vs market
20202024
Debt / equity
0.25×
This company
0.62×
Market median
+60% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
PM Chief Auditor | Chief Auditor | 2022 |
HO Auditor Substitute | Auditor Substitute | 2022 |
JM Chief Executive Officer | Chief Executive Officer | 2023 |
| Former (3) | ||
GW Chief Auditor | Chief Auditor | 2022 – 2022 |
OC Auditor Substitute | Auditor Substitute | 2020 – 2022 |
JH Chief Executive Officer | Chief Executive Officer | 2022 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2023 | |
| Board of Directors | 2024 | |
| Chairman | 2024 | |
| Board of Directors | 2023 | |
| Former (10) | ||
| Chairman | 2023 – 2024 | |
| Board of Directors | 2023 – 2023 | |
| Deputy Board Member | 2022 – 2022 | |
| Chairman | 2023 – 2023 | |
| Board of Directors | 2022 – 2023 | |
| Deputy Board Member | 2023 – 2023 | |
| Board of Directors | 2020 – 2022 | |
| Deputy Board Member | 2020 – 2022 | |
| Board of Directors | 2020 – 2022 | |
| Board of Directors | 2020 – 2023 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Glycorex Transplantation AB (publ) (this company)
GLYCOREX MSA DE CVGLYCOREX TRANSPLANTATION PTY LTDGlycorex Msa De CvGlycorex Transplantation Pty LtdBoard members of Glycorex Transplantation AB (publ) also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Martin Henriksson | Chief Auditor | 0 companies |
| Henry Oskar Stefan Svensson | Auditor Substitute | 0 companies |
| Geert, Walther Nygaard | Chief Auditor | 0 companies |
| Ola Christopher Carelius Larsmon | Auditor Substitute | 0 companies |
| Johan Henrik Gustav Lavén | Chief Executive Officer | 0 companies |
| Johan Martin Ingemar Nilsson | Chief Executive Officer | 0 companies |
| Björn Oskar Larsson | Chairman | 0 companies |
| Clas Gunnar Runnberg | Board of Directors | 0 companies |
| Tomas Westergren | Deputy Board Member | 0 companies |
| Joakim Mikael Jagorstrand | Board of Directors | 0 companies |
| Nils Kai Fritiof Siegbahn | Chairman | 0 companies |
| Leni Christina von Bonsdorff-Lindeberg | Board of Directors | 0 companies |
| Frida Lovisa Thorsén | Deputy Board Member | 0 companies |
| Claes Gustav Tyko Blanche | Board of Directors | 0 companies |
| Nils Johan Pontus Nobréus | Deputy Board Member | 0 companies |
| Sven Christer Ahlberg | Board of Directors | 0 companies |
| Per Roland Caj Frösing | Board of Directors | 0 companies |
| Kurt Gösta Ingemar Nilsson | Chairman | 0 companies |
| Jan Fredrik Johansson | Board of Directors | 0 companies |
| Lars Åke Torbjörn Axelsson | Board of Directors | 0 companies |